{"nctId":"NCT00312572","briefTitle":"Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain","startDateStruct":{"date":"2003-06"},"conditions":["Osteoarthritis"],"count":204,"armGroups":[{"label":"BTDS10/20","type":"EXPERIMENTAL","interventionNames":["Drug: Buprenorphine transdermal patch"]},{"label":"BTDS 20","type":"EXPERIMENTAL","interventionNames":["Drug: Buprenorphine transdermal patch"]}],"interventions":[{"name":"Buprenorphine transdermal patch","otherNames":["Butrans™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n\\- osteoarthritis of the hip or knee taking a regularly scheduled regimen of hydrocodone/ acetaminophen for their osteoarthritis OA pain.\n\nExclusion Criteria:\n\n* currently have condition requiring a stable regimen of acetaminophen (APAP).\n* a history of chronic conditions, other than OA of the hip or knee joints, requiring frequent, intermittent analgesic therapy.\n\nOther protocol-specific exclusion/inclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Subjects Who Completed the 14-day Double-blind Phase.","description":"The indicator variable was 1 = completion, and 0 = noncompletion. For the primary efficacy analysis, the percentage of subjects who completed the double-blind phase was computed with its 95% confidence interval (CI) for each treatment regimen (starting dose of BTDS 10 or BTDS 20) across and within baseline Vicodin® stratum (15 to 22.5mg/day vs \\>22.5 to 30 mg/day as determined by the daily average hydrocodone dose during the run-in period).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"84","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":101},"commonTop":["Application site pruritus","Headache","Nausea","Somnolence","Vomiting NOS"]}}}